Skip to main content
SpringerLink
Log in

Efficacité et tolérance d’une trithérapie antirétrovirale à base de ténofovir disoproxil-emtricitabine-éfavirenz chez les patients naïfs infectés par le VIH-1 à Bobo Dioulasso (Burkina Faso, 2009–2011)

Efficacy and tolerability of antiretroviral therapy containing tenofovir disoproxil fumarate-emtricitabine-efavirenz in treatment-naive patients infected with HIV-1 in Bobo Dioulasso (Burkina Faso, 2009–2011)

  • Thérapeutique / Therapeutics
  • Published:
Bulletin de la Société de pathologie exotique

Résumé

L’objectif de cette étude était d’évaluer l’efficacité et la tolérance clinique de l’association TDF/FTC/EFV dans le traitement de l’infection à VIH-1. Il s’agissait d’une étude rétrospective, descriptive, qui s’est déroulée à l’hôpital de jour de Bobo-Dioulasso sur une période de 29 mois. Au total 196 patients ont été inclus. La durée médiane de suivi était de sept mois IQR [5–14 mois]. L’âge médian était de 37 ans IQR [31–45]. À l’initiation du traitement ARV, la médiane de l’indice de masse corporelle était de 19 IQR [17–22]; la médiane des lymphocytes TCD4 était de 201/μl IQR [74–298]. Au cours du suivi, nous avons dénombré 25 décès (12,8 %). La charge virale ARN VIH-1 plasmatique était indétectable chez 91,9 % des patients (124/135) à six mois de traitement. La plupart des effets indésirables du traitement étaient d’ordre neurosensoriel (40,5 %). L’association TDF/FTC/EFV (ténofovir disoproxil fumarate-emtricitabineéfavirenz) a montré une bonne efficacité dans le traitement de l’infection à VIH-1 en première intention de même qu’une bonne tolérance clinique.

Abstract

The objective of this study was to evaluate the effectiveness and the clinical tolerance of a combination containing TDF/FTC/EFV in the treatment of HIV infection. This was a retrospective and descriptive study which included 196 adults infected by HIV-1 and treated by a combination containing TDF/FTC/EFV during 29 months in the daily hospital of Bobo Dioulasso. The median duration of follow-up was 7 months IQR [5–14 month]. The median age was 37 years IQR [31–45].With the initiation of treatment ARV, the median of the index of body mass was of 19 IQR [17–22]. The median of the lymphocytes TCD4 was 201/μl IQR [74–298/μl]. During the follow-up, we reported 25 deaths (12.8%). HIV-1 RNA plasma viral load was undetectable in 91.9% of the patients (124/135) at six months of treatment. The majority of the adverse effects of the treatment were of a neurosensory nature (40.5%). The TDF/FTC/EFV combination showed a good effectiveness in the treatment of the infection with HIV-1 in the first intention just as a good clinical tolerance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Deeks ED, Perry CM (2010). Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs 70(17): 2315–2338

    Article  PubMed  CAS  Google Scholar 

  2. Derache A, Maiga AI, Traore O, et al (2008). Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 62(3):456–463

    Article  PubMed  CAS  Google Scholar 

  3. Eholié SP, Girard P-M, Bissagnéné E, et al (2009) Mémento thérapeutique du VIH/sida en Afrique. Paris, Doin

    Google Scholar 

  4. Eshleman SH, Laeyendecker O, Parkin N, et al (2009) Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 23(7):845–852

    Article  PubMed  CAS  Google Scholar 

  5. Etard JF, Ndiaye I, Thierry-Mieg M, et al (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20:1181–1189

    Article  PubMed  Google Scholar 

  6. Gallant JE, DeJesus E, Arribas JR, et al (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354(3):251–260

    Article  PubMed  CAS  Google Scholar 

  7. Goicoechea M, Liu S, Best B, et al (2008). Greater tenofovirassociated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197(1):102–108

    Article  PubMed  CAS  Google Scholar 

  8. Katz IJ, Gerntholtz T, Naicker S (2011) Africa and nephrology: the forgotten continent. Nephron Clin Pract 117(4):c320–c327

    Article  PubMed  Google Scholar 

  9. Landman R, Poupard M, Diallo M, et al (2009) Tenofoviremtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) 8(6):379–384

    Article  Google Scholar 

  10. Lawn SD, Myer L, Orrell C, et al (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19(18): 2141–2148

    Article  PubMed  Google Scholar 

  11. Malik A, Abraham P, Malik N (2005) Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect 51(2):E61–E65

    Article  PubMed  Google Scholar 

  12. OMS (2010). Antiretroviral therapy for HIV infection in adults and adolescents; Recommendations for a public health approach [http://www.who.int/hiv/pub/arv/adult2010/en/]

    Google Scholar 

  13. OMS (2006) — Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access recommendations for a public health approach

    Google Scholar 

  14. Ouattara B, Kra O, Yao H, et al (2011) Particularités de l’insuffisance rénale chronique chez des patients adultes noirs hospitalisés dans le service de médecine interne du CHU de Treichville. Nephrol Thér 7(7):531–534

    Article  PubMed  Google Scholar 

  15. Patel SM, Zembower TR, Palella F, et al (2007) Early onset of tenofovir-induced renal failure: case report and review of the literature. Scientific World Journal 7:1140–1148

    Article  PubMed  CAS  Google Scholar 

  16. Pozniak AL, Gallant JE, DeJesus E, et al (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/ lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes—a 96-week analysis. J Acquir Immune Defic Syndr 43(5):535–540

    PubMed  CAS  Google Scholar 

  17. Pujari S, Dravid A, Gupte N, et al (2008) Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India. Medscape J Med 10(8):196

    PubMed  Google Scholar 

  18. Seydi M, Diop SA, Dieng AB, et al (2009) Étude de la tolérance d’une trithérapie antirétrovirale de première intention associant zidovudine, lamivudine et efavirenz à Dakar, Sénégal. Bull Soc Pathol Exot 102(2):99–100 [http://www.pathexo.fr/documents/articles-bull/T102-2-3328-2p.pdf]

    PubMed  CAS  Google Scholar 

  19. Szczech LA, Gange SJ, van der Horst C, et al (2002) Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61(1):195–202

    Article  PubMed  Google Scholar 

  20. Tebit DM, Sangaré L, Tiba F, et al (2009) Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso. J Med Virol 81(10):1691–1701

    Article  PubMed  CAS  Google Scholar 

  21. Weiner NJ, Goodman JW, Kimmel PL (2003) The HIVassociated renal diseases: current insight into pathogenesis and treatment. Kidney Int 63(5):1618–1631

    Article  PubMed  Google Scholar 

  22. Yeni P (2010).Prise en charge des personnes infectées par le VIH. Recommandations du groupe d’experts. La documentation française

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hôpital de jour et service des maladies infectieuses et tropicales du Centre hospitalier universitaire Souro Sanou, Bobo Dioulasso, Burkina

    J. Zoungrana, A. Hema, G. Bado, G. E. A. Poda, E. B. Kamboulé, F. N. Kaboré, I. Soré & A. B. Sawadogo

Authors
  1. J. Zoungrana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Hema
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Bado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. E. A. Poda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. B. Kamboulé
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. N. Kaboré
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Soré
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. B. Sawadogo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Zoungrana.

Additional information

Communication présentée lors de la 6e conférence francophone VIH/Sida organisée par l’AFRAVIH. Genève et lors des 16e Journées des sciences de la santé de Bobo-Dioulasso le 10 mai 2012

About this article

Cite this article

Zoungrana, J., Hema, A., Bado, G. et al. Efficacité et tolérance d’une trithérapie antirétrovirale à base de ténofovir disoproxil-emtricitabine-éfavirenz chez les patients naïfs infectés par le VIH-1 à Bobo Dioulasso (Burkina Faso, 2009–2011). Bull. Soc. Pathol. Exot. 106, 239–243 (2013). https://doi.org/10.1007/s13149-013-0313-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13149-013-0313-x

Mots clés

Keywords

Search

Navigation